• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

3.780 -0.110 (-2.83%)
Streaming Delayed Price Updated: 9:30 AM EDT, Mar 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
February 26, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
February 24, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
February 24, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
February 20, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
February 11, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
February 05, 2026
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
January 16, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 19, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Biotech Valuations Rise as New Clinical Platforms Show Progress
November 24, 2025
Via Investor Brand Network
News headline image
Biotech Valuations Rise as New Clinical Platforms Show Progress
November 24, 2025
From BioMedWire
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
November 21, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® Beverage Rollout – Eyes $100M+ in 2026
November 06, 2025
Via AB Newswire
News headline image
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
November 06, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
November 03, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
October 29, 2025
Via Investor Brand Network
News headline image
IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders
October 29, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
October 29, 2025
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
October 23, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 17, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
October 08, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 19, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Advancing Cancer Research Brings New Hope for Patients Worldwide
September 17, 2025
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Advancing Cancer Research Brings New Hope for Patients Worldwide
September 17, 2025
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Intellectual Property
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
August 29, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 22, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma
August 18, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
August 07, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025
July 24, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Health In Tech (NASDAQ: HIT) Posts Blowout Q2, Stock Responds – HIT, SNYR, PNPN.V/PNPNF in Breakout Zone; See More to Watch Inside
July 22, 2025
Via AB Newswire
Topics Artificial Intelligence
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 18, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap